The $10,000 Question Every Patient Should Ask Before Booking
Key Takeaways
- Not all stem cell providers are equal: a board-certified MD performing an ultrasound-guided injection is a fundamentally different procedure than a mid-level provider doing a “blind” injection at a med spa.
- The FDA draws a critical line between 361-compliant and 351-regulated stem cell products — knowing the difference may protect your health and your money.
- Legitimate clinics welcome hard questions about credentials, imaging requirements, extraction methods, and contingency plans. Clinics that deflect those questions are a warning sign.
- If an initial treatment falls short, an evidence-informed follow-up protocol — including PRP booster therapy — exists. Any credible provider should explain this before you sign anything.
You’ve done the research. You’ve watched the videos. You’re tired of cortisone shots that wear off in six weeks, and you’re not ready to accept that a knee replacement is your only option. Stem cell therapy feels like the answer — but the stem cell industry is also one of the most unregulated spaces in American medicine, and the difference between a legitimate clinic and a predatory one is not always obvious from a website.
This guide gives you the exact framework we use at Houston Regenerative Medicine to evaluate whether any regenerative medicine provider — including us — is qualified to treat you. Use it as your checklist before you book a single consultation.
The eight questions below are not optional. They are the standard.
Is the Doctor Actually a Doctor? — Vetting Credentials Before Anything Else
The single most important variable in any stem cell procedure is not the product being injected. It’s the person holding the needle.
Regenerative medicine sits at the intersection of orthopedics, interventional sports medicine, and cellular biology. The physician performing your procedure should hold an active MD or DO license, carry board certification in a relevant specialty (orthopedics, physical medicine and rehabilitation, or interventional sports medicine), and be the one performing the injection — not delegating it to a registered nurse or physician assistant.
This distinction matters enormously. In Texas, as in most states, the scope of practice for mid-level providers is legally restricted. A procedure involving the extraction of biologic material from your bone marrow or adipose tissue, processed in a lab and re-injected under imaging guidance, is not within the standard scope of a med spa or a non-physician-led wellness center.
What to Look Up on the Texas Medical Board
Before your consultation, take five minutes to verify the provider independently. Visit the Texas Medical Board license lookup at tdlr.texas.gov and search the physician’s name. Confirm:
- Their license is active (not lapsed, suspended, or on probation)
- Their listed specialty aligns with musculoskeletal or interventional medicine
- No disciplinary actions are on record
This is a free, public search that takes under two minutes. Any legitimate provider will encourage you to do it. If a clinic discourages this step, that is a red flag.
Why No MRI Means No Treatment — The Mandatory Pre-Consultation Evaluation
A credible regenerative medicine provider will not discuss treatment options — let alone quote you a price — until they have reviewed current imaging of the affected joint.
Here’s why this is non-negotiable: stem cell therapy is not a universal injection. The appropriate treatment protocol depends entirely on the structural diagnosis. A grade-II rotator cuff partial tear responds differently from a grade-IV full-thickness tear. Early-stage knee osteoarthritis with preserved joint space is a fundamentally different clinical picture than bone-on-bone arthritis with subchondral sclerosis. Without a current MRI (typically within the last 12–18 months) and weight-bearing X-rays, a physician cannot responsibly tell you whether you are a candidate, what extraction method is appropriate, or what realistic outcomes look like.
If a clinic skips imaging and goes straight to pricing, walk away. That is not a medical consultation — it is a sales call.
At Houston Regenerative Medicine, every patient undergoes a thorough review of their imaging before any protocol is proposed. We look at the structural damage, we look at the patient’s overall health picture, and we tell patients honestly when they are not a good candidate. Turning away patients who won’t benefit from the procedure is not bad business — it is what “do no harm” actually looks like in practice.
“Blind” Injections vs. Ultrasound-Guided Precision — Why Placement Is Everything
This is the technical point that separates a legitimate orthopedic regenerative procedure from an expensive injection that may accomplish very little.
A “blind” injection means the provider is placing the needle based on anatomical landmarks alone — no real-time imaging, no visual confirmation that the biologic material is reaching the intended tissue. For a superficial structure in a straightforward patient, a skilled clinician can achieve reasonable accuracy this way. But for the joints most commonly treated with stem cells — the knee, hip, shoulder, and spine — the anatomy is complex, the target tissue is small, and the margin for error is significant.
Ultrasound-guided injection uses real-time imaging to visualize the needle tip as it advances toward the target. The physician can confirm placement within the intra-articular space, the tendon sheath, or the specific zone of cartilage degeneration before the biologic material is released. This is not a luxury upgrade. When you are investing thousands of dollars in a cellular therapy, ensuring that the cells actually reach the damaged tissue is a clinical necessity.
Ask your prospective provider directly: “Do you use ultrasound or fluoroscopic guidance for all regenerative injections?” The answer should be an unequivocal yes. If the response is hedged — “we do when it’s necessary” or “for certain joints” — press for specifics. For knee, hip, and shoulder procedures, image guidance should be the standard, not the exception.
Where Do the Stem Cells Come From? — Comparing Bone Marrow vs. Adipose Extraction
Autologous stem cell therapy — meaning cells harvested from your own body — is the clinical gold standard for orthopedic regenerative procedures. The two primary harvest sites are bone marrow and adipose (fat) tissue, and they are not interchangeable.
Bone Marrow Aspirate Concentrate (BMAC) vs. Adipose-Derived Stem Cells
| Factor | Bone Marrow Aspirate (BMAC) | Adipose-Derived (Fat) |
| Harvest Site | Posterior iliac crest (hip bone) | Abdomen or flank (lipoaspiration) |
| Stem Cell Type | Mesenchymal stem cells (MSCs), hematopoietic progenitors | Mesenchymal stem cells (MSCs), stromal vascular fraction |
| Relative Cell Yield | Lower volume, higher potency per cell | Higher volume, more cells per harvest |
| Patient Discomfort | Moderate (local anesthesia; brief pressure sensation) | Mild to moderate (local anesthesia; similar to minor lipo) |
| Recovery Time | 24–48 hours of soreness at the harvest site | 24–72 hours of soreness at the harvest site |
| Best Clinical Application | Bone healing, cartilage repair, early-to-moderate osteoarthritis | Soft tissue repair, tendon/ligament conditions, and larger volume needs |
| Processing Requirement | Centrifugation to concentrate cells | Enzymatic or mechanical processing to isolate SVF |
At Houston Regenerative Medicine, we use a dual-source approach — harvesting from both adipose tissue and bone marrow when clinically appropriate — because the synergy between the two cell populations may support more comprehensive tissue regeneration than either source alone. This is one of the key differentiators between our protocols and single-source providers.
Ask any clinic: “Do you use bone marrow, fat, or both — and how do you decide which is right for my condition?” A physician who can answer this question specifically, based on your imaging and diagnosis, is demonstrating genuine clinical reasoning. A provider who gives the same answer to every patient is not.
What About Exosomes and Umbilical Stem Cells? — Understanding Exogenous Options
Some clinics offer regenerative products derived from donor tissue — most commonly exosomes or umbilical cord-derived cells. These are exogenous products, meaning they come from an outside source rather than your own body, and they occupy a meaningfully different regulatory and clinical space.
Exosomes are not cells. They are extracellular vesicles — essentially microscopic “signal packets” released by cells that carry proteins, growth factors, and genetic material. The theory is that exosomes can communicate with damaged tissue and stimulate the body’s own repair processes. Early research is promising, but as of 2025, exosome therapies for musculoskeletal conditions remain investigational. The FDA has not approved any exosome product for injection, and clinics marketing exosomes as an established, proven treatment are operating in a regulatory gray zone.
Umbilical cord-derived products (including Wharton’s Jelly and cord blood-derived cells) are sourced from consented post-birth donations. Reputable suppliers screen donors rigorously for infectious diseases and genetic abnormalities, and the tissue is processed under strict sterile protocols. However, these are allogeneic products — meaning they come from a different person’s biology — and the long-term immune response data for orthopedic applications is still maturing.
If a clinic offers these products, ask three questions: Who is the tissue supplier? What screening and sterility certifications does the lab hold? And is this product being used under an FDA-reviewed IND (Investigational New Drug) application or under a 361 exemption?
How to Decode a Clinic’s Claims — Realistic Success Rates vs. Red-Flag Guarantees
No physician can guarantee you will be pain-free after stem cell therapy. Any clinic that does is either misinformed or deliberately misleading.
Here is what the honest clinical picture looks like: in peer-reviewed studies of bone marrow aspirate concentrate for knee osteoarthritis, a meaningful percentage of patients report clinically significant pain reduction and functional improvement at 12 months, with outcomes varying across published case series. But “meaningful improvement” is not “complete resolution,” response rates vary by disease severity, and the research base, while growing, is still younger than the evidence supporting hip or knee replacement.
What you are looking for in a legitimate provider is not a guarantee — it is a calibrated, honest probability.
Red flags to watch for:
- “100% success rate” — not statistically possible across a patient population
- “Guaranteed results or your money back” — not a medical standard; it’s a marketing tactic
- “We can treat anything” — legitimate regenerative medicine has specific indications and contraindications
- No mention of candidates who are not appropriate — a credible provider turns away patients who won’t benefit
Ask directly: “What percentage of your patients with my condition and severity achieve meaningful improvement? And what does your data look like at 12 and 24 months?”
Understanding FDA Regulations — The 361 vs. 351 Pathways Every Patient Must Know
This is the section most clinics hope you never ask about. Understanding it takes five minutes and may protect you from a significant medical and financial risk.
The FDA regulates human cellular and tissue-based products (HCT/Ps) under two primary frameworks:
Section 361 of the Public Health Service Act covers minimally manipulated, homologous-use tissue. In plain language: if a clinic harvests cells from your own body (autologous), processes them minimally (centrifugation, not chemical or genetic alteration), and re-injects them into a structurally similar tissue (cartilage cells back into a joint), this may qualify for 361 status — meaning it does not require a full FDA drug approval process. Autologous BMAC and adipose-derived stem cell procedures at qualified clinics typically fall under this framework.
Section 351 applies to products that are more than minimally manipulated, used for non-homologous purposes, or manufactured from donor tissue for commercial distribution. These products are regulated as biological drugs and legally require FDA approval — meaning an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application for clinical trials.
Here is the critical implication: if a clinic is injecting you with a commercially purchased exosome product, an umbilical cord-derived product, or any “off-the-shelf” cellular therapy that has not received FDA approval or is not part of an approved clinical trial, that procedure may be operating outside of legal compliance. The FDA has issued warning letters to numerous clinics for exactly this violation.
Ask any clinic: “Is this product 361-compliant, or is it regulated under 351? If it’s a 351 product, can you show me the IND or BLA documentation?”
What Happens If the First Treatment Doesn’t Work? — The Contingency Plan Conversation
This is the question almost no clinic addresses proactively — and it is one of the most important conversations you can have before committing to treatment.
A credible post-treatment contingency framework looks something like this:
- At 6–8 weeks: A structured follow-up to assess early response. Imaging or functional assessment may be used to evaluate whether the treated area shows signs of tissue response.
- At 3 months: If improvement is modest or plateauing, a PRP booster protocol is often the first intervention — delivering a concentrated dose of growth factors to the treatment site to support ongoing cellular activity.
- At 6 months: If the response remains insufficient, a second stem cell extraction and injection may be appropriate. The decision depends on the degree of structural damage, the patient’s overall health, and whether the initial procedure was technically optimal.
- At 12 months: For patients with advanced joint degeneration who have not achieved adequate relief, a candid conversation about surgical options — including when a joint replacement is the right choice — is part of ethical patient care.
The goal is never to keep a patient cycling through regenerative treatments indefinitely. The goal is to achieve a meaningful, durable outcome.
PRP Boosters — How Platelet-Rich Plasma Maximizes Stem Cell Results
Platelet-Rich Plasma therapy is not a standalone alternative to stem cell treatment — it is a precision tool that can meaningfully amplify and extend stem cell outcomes when used strategically.
Here’s the biology in accessible terms: your blood contains platelets, which are tiny cell fragments loaded with growth factors — proteins that signal tissue repair, stimulate new blood vessel formation, and modulate the inflammatory environment. PRP is created by drawing a small amount of your blood, spinning it in a centrifuge to concentrate the platelet layer, and injecting that concentrate into the treatment site. The result is a localized surge of growth factor signaling.
When combined with stem cell therapy, PRP serves two distinct functions. First, it creates a more favorable biological environment at the injection site before stem cells are introduced, essentially “priming” the tissue. Second, when used as a booster at the 3–6 month mark, it can re-stimulate cellular activity in patients whose initial response has plateaued.
The synergistic effect of combining stem cells with PRP is one of the core differentiators in our treatment protocols. Published research on combined PRP and BMAC therapy for knee osteoarthritis shows outcomes that consistently outperform either therapy used in isolation.
Ask a prospective clinic: “Is PRP included in my stem cell protocol, or is it a separate add-on? And at what point would you recommend a PRP booster if my results plateau?”
What to Do Next
If you’ve read this guide, you now know more about evaluating a regenerative medicine provider than most patients who have already had the procedure.
The next step is a conversation — not a commitment.
At Houston Regenerative Medicine, we offer a free consultation specifically designed for patients in the research phase. We’ll review your imaging, walk you through whether you’re a strong candidate for autologous stem cell extraction methods, explain exactly which protocol we’d recommend and why, and answer every question on this checklist directly. If you’re not a good candidate, we’ll tell you that too.
Our board-certified interventional physicians have helped thousands of patients avoid unnecessary surgery since 2012.
The Wolverine Peptide Stack: A Physician’s Guide to Accelerated Injury Recovery, Muscle Preservation, and Regenerative Healing
